Table 3.
Ongoing clinical trials evaluating PARPi in combination with targeted agents in HER2 negative BC
| PARP inhibitor | Phase | Study population/ tumor type | Treatment | NCT |
|---|---|---|---|---|
| Olaparib | I/II | Recurrent ovarian, fallopian tube, peritoneal or TNBC patients with gBRCA mutation | Olaparib+ Cediranib Maleate | NCT01116648 |
| Olaparib | II | Metastatic or unresectable solid tumors (TNBC, NSCLC, SCLC and pancreatic adenocarcinoma) | Olaparib+ Cediranib Maleate | NCT02498613 |
| Fluzoparib | I | Recurrent ovarian or TNBC patients and subjects with deleterious BRCA mutation | Fluzoparib + Apatanib | NCT03075462 |
| Olaparib | I | Recurrent TNBC or HGSOC | Olaparib + PI3K inhibitor (BKM 120 or BYL719) | NCT01623349 |
| Olaparib | I/II | Recurrent endometrial, TNBC, and ovarian, primary peritoneal, or fallopian tube cancer | Olaparib + mTORC1/2 inhibitor (AZD2014) & AKT inhibitor (AZD5363) | NCT02208375 |
| Olaparib | I | Metastatic, unresectable or recurrent solid tumors (ovarian, fallopian tube, or primary peritoneal and TNBC) | Olaparib + Onalespib (HSP90 inhibitor) | NCT02898207 |